The Regenerative Sciences litigation - formally US v. Regenerative Sciences, LLC - established the FDA’s authority to regulate stem cell and HCT/P products as drugs when they fail the 361-pathway criteria. The case ran from 2009 through appellate affirmation in 2014 and remains the foundational precedent shaping FDA enforcement of regen medicine marketing today. Understanding the case is essential to understanding why regen clinic marketing operates under the rules it does.
The background
Regenerative Sciences offered an autologous stem cell therapy called Regenexx for orthopedic conditions - specifically, a protocol involving extracting mesenchymal stem cells, culturing them in the laboratory to expand their number, and then reinjecting them into the patient.
The company’s position was that because the cells were the patient’s own (autologous), the treatment was the practice of medicine and not subject to FDA drug regulation. The FDA’s position was that the expansion step - culturing cells to increase their number - constituted more than minimal manipulation, which took the product out of the 361 pathway and into 351 drug/biologic territory.
What the court decided
The district court and Court of Appeals for the DC Circuit both ruled in favor of the FDA. The key holdings:
- The cultured cell product was a drug. The culturing step constituted more than minimal manipulation, pushing the product out of the 361 pathway.
- As an unapproved drug, it could not be marketed without FDA approval. Autologous source material does not exempt a product from drug regulation.
- The FDA had jurisdiction.Even for in-state, autologous treatments, the FDA’s authority under the FD&C Act applied.
- Marketing representations affected regulatory status. How the product was marketed - what claims were made - was part of the analysis of what the product was legally.
What the case established for regen marketing
The autologous/patient-own argument is not a defense
A common regen clinic marketing framing - “these are your own cells, not a drug” - was specifically rejected in this case. The autologous nature of the material doesn’t automatically place a product outside FDA drug regulation. The processing, manipulation, and use determine the regulatory status, not the source.
Marketing claims are part of the regulatory analysis
The court accepted that how a product is marketed affects its regulatory classification. Marketing claims that position a product as treating specific diseases convert the product into an unapproved drug for those indications - even if the product itself would otherwise qualify for a different pathway.
Practice of medicine has limits
“This is the practice of medicine” is not a blanket shield against FDA regulation. When the clinical practice involves manufacturing an unapproved drug, FDA jurisdiction applies even though clinical practice itself is typically state-regulated.
Minimal manipulation is enforced narrowly
The court upheld the FDA’s narrow interpretation of minimal manipulation. Processing steps that change the relevant biological characteristics of cells - including cell expansion through culturing - exceed minimal manipulation. This is why regen practice marketing that emphasizes advanced processing, activation, or enhancement signals 351-pathway territory.
Ongoing effects on regen marketing
Marketing language matters to regulatory classification
The specific marketing language your practice uses isn’t just a compliance-advertising issue - it can affect how the underlying product is regulatorily classified. Marketing that implies more-than-minimal manipulation, systemic effects, or non-homologous use moves the product out of 361 pathway eligibility.
The FDA feels it has affirmed authority
The appellate affirmation gave the FDA confidence in its approach to regen medicine enforcement. Subsequent warning letter campaigns, including the sustained HCT/P enforcement initiative, trace their authority to Regenerative Sciences.
Industry fragmentation followed
After the litigation, the stem cell industry fragmented: some operations continued offering expanded-cell therapies outside the US or under specific FDA-approved pathways; others shifted to 361-compliant protocols without cell expansion. Marketing claims needed to match the specific approach.
Non-expansion regen practices still face enforcement
Even practices operating without cell expansion face enforcement when their marketing claims push the product outside 361 eligibility in other ways - disease- treatment claims, systemic-effect claims, non-homologous-use claims. The pathway analysis applies to marketing language, not just physical processing.
Specific marketing lessons
Lesson 1: Don’t market cell expansion or activation
If your practice uses minimally-manipulated cells under the 361 pathway, marketing should reflect that. Language about “expanded,” “cultured,” “activated,” or “enhanced” cell products signals non-361 processing - which converts your marketing into unapproved drug marketing.
Lesson 2: Don’t market disease treatment
Disease-treatment claims convert regen products into unapproved drugs for those indications. The Regenerative Sciences court accepted the marketing-affects-classification principle. Disease-specific marketing has direct regulatory consequences beyond the marketing-compliance issue.
Lesson 3: Don’t rely on “practice of medicine” framing
Marketing that positions services as pure practice of medicine - beyond FDA reach - doesn’t actually work. Regenerative Sciences specifically rejected this framing. Clinical practice is state-regulated; products manufactured or administered are subject to FDA authority.
Lesson 4: Match marketing to the specific processing
If you perform same-day, minimally-manipulated, homologous-use autologous HCT/P procedures, market that specifically. Accurate marketing of what you actually do is both compliance-safe and credible to informed patients. Vague or aggressive marketing that overreaches the actual practice creates exposure.
Related cases and precedent
- US v. Liveyon. Subsequent FDA action against a HCT/P distributor for marketing birth-tissue products outside the 361 pathway.
- US v. US Stem Cell Clinic. Court-enforced injunction against stem cell clinic operations that failed FDA pathway requirements.
- FDA Regenerative Medicine Framework.2017 FDA guidance framework building on Regenerative Sciences principles, clarifying FDA expectations for regenerative medicine products.
- 21st Century Cures Act Section 3033.Congressional creation of the Regenerative Medicine Advanced Therapy (RMAT) designation as an accelerated approval pathway.
Frequently asked questions
Did Regenerative Sciences effectively shut down stem cell medicine in the US?
No - but it reshaped how stem cell medicine can operate in the US. Practices offering same-day, minimally-manipulated, homologous-use autologous HCT/P procedures continue to operate under the 361 pathway. Practices doing cell expansion or non-homologous applications need FDA approval pathways.
Can I still offer Regenexx-style treatments in the US?
The specific Regenexx protocol involved cell expansion that requires FDA approval. Some Regenexx providers operate protocols modified to fit the 361 pathway (without expansion); others operate outside the US.
Does this case affect PRP marketing?
Yes. PRP is an HCT/P subject to the same 361 pathway analysis. Marketing claims that push PRP products outside 361 eligibility - typically through disease-treatment claims - have the same regulatory effect.
What about exosomes specifically?
Exosome products face similar pathway analysis. The FDA has generally taken the position that most therapeutically- marketed exosome products do not qualify for the 361 pathway due to processing or use characteristics. Enforcement has been active in this category.
How do I know which pathway my practice operates under?
Consult healthcare regulatory counsel familiar with HCT/P regulation. The pathway analysis requires detailed understanding of your specific products, processing steps, and intended uses - plus current FDA interpretation, which evolves. This is not a self-assessment question.
Is there case law I should monitor for updates?
HCT/P regulatory litigation continues. FDA warning letters, consent decrees, and related cases publish regularly. Your healthcare regulatory counsel should monitor case law developments affecting your specific specialty.